Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd (KMDA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products for rare and serious conditions. Its news flow reflects activity across commercial operations, clinical programs, plasma collection, and corporate strategy.
On this page, readers can follow Kamada news related to its proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Company announcements frequently discuss revenue trends, adjusted EBITDA, and guidance, highlighting the contribution of its Proprietary Products and Distribution segments, including biosimilar launches in Israel and supply agreements in markets such as Canada.
News items also cover clinical and post-marketing research, including updates on the InnovAATe Phase 3 trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency and its subsequent discontinuation following an interim futility analysis, as well as the SHIELD study evaluating CYTOGAM in high-risk kidney transplant recipients. Regulatory and operational milestones, such as FDA approval of the Houston, Texas plasma collection center and expansion of plasma collection capacity across Kamada’s three Texas sites, are recurring topics.
Investors and followers of KMDA stock can use this feed to track quarterly and annual financial results, guidance updates, tender awards like the Canadian Blood Services supply extension, and participation in healthcare and investor conferences. Regularly reviewing this page provides a consolidated view of Kamada’s commercial progress, R&D developments, and strategic initiatives as reported in its press releases and related filings.
Kamada Ltd. has announced the appointments of Jon R. Knight as Vice President of U.S. Commercial Operations and Jonathan Ward as Director of Facilities and Construction. These changes aim to enhance U.S. operations and expand plasma collection capabilities, especially related to the company’s recently acquired portfolio of four FDA-approved plasma-derived hyperimmune products. Knight's experience in plasma product commercialization and Ward's expertise in facility management are expected to drive sales growth and new center openings, respectively.
Kamada Ltd. (NASDAQ: KMDA) will release its financial results for Q4 and FY 2021 on March 15, 2022. A conference call for investors will follow at 8:30 AM ET, where management will discuss results and answer questions. Kamada is a leader in the plasma-derived biopharmaceutical industry, focusing on expanding its product portfolio, including FDA-approved treatments like GLASSIA® and CYTOGAM®. The company aims to drive growth through robust development and manufacturing capabilities.
Kamada has acquired a portfolio of four FDA-approved plasma-derived hyperimmune products from Saol Therapeutics for $95 million upfront and up to $50 million in sales milestones through 2034. The global revenue from the products is estimated between $40 million to $45 million, with 75% of sales from the U.S. and 20% from Canada. This acquisition positions Kamada to become a global leader in plasma-derived therapies, enhancing its commercial capabilities in the U.S. market while gaining access to eight additional international markets, mainly in the MENA region.
Kamada Ltd. (NASDAQ: KMDA) reported Q3 2021 revenues of $23.0 million, down from $35.3 million in Q3 2020. The company acquired a portfolio of four FDA-approved plasma-derived products from Saol Therapeutics, expected to generate annual revenues of $40 million to $45 million. The transition of GLASSIA® manufacturing to Takeda is complete, moving to a royalty phase in 2022. The company aims to expand its plasma collection capabilities in the U.S. while advancing the Phase 3 InnovAATe trial for Inhaled AAT. As of September 30, 2021, cash and equivalents stood at $99.8 million.
Kamada Ltd. (NASDAQ: KMDA), a plasma-derived biopharmaceutical company, will announce its financial results for the three and nine months ending September 30, 2021, on November 22, 2021. An investment community conference call is scheduled for the same day at 8:30 AM ET, allowing stakeholders to discuss results. Kamada is recognized for its products, GLASSIA and KEDRAB, supported by significant partnerships. The company aims to enhance its growth through commercial products and a robust development pipeline, including treatments for AAT deficiency and COVID-19.
Kamada Ltd. (NASDAQ: KMDA) reported second-quarter 2021 revenues of $24.2 million, down from $33.1 million in Q2 2020. Gross profit decreased to $9.1 million, yielding a gross margin of 37%. The company completed a workforce downsizing, anticipated to reduce annual labor costs by 10%. Net income fell to $0.9 million ($0.02 per share) from $3.5 million ($0.10 per share). Adjusted EBITDA was $2.4 million. Kamada is advancing its Phase 3 InnovAATe trial for inhaled AAT and plans to expand plasma collection centers.
Kamada Ltd. (NASDAQ: KMDA) will release its financial results for Q2 2021 on August 11, before U.S. markets open. A conference call to discuss these results will follow at 8:30 AM ET, available via telephone or a live webcast. The company's leading products include GLASSIA® and KEDRRAB®, with GLASSIA being the first FDA-approved liquid AAT product. Kamada is also advancing clinical trials for inhaled AAT and a hyperimmune IgG product for COVID-19. FIMI Opportunity Fund is the lead shareholder, owning approximately 21% of the company.
Kamada's KEDRAB® has received a significant label update from the FDA, making it the first and only human rabies immune globulin (HRIG) clinically studied in children. This new indication allows for KEDRAB's use in individuals of all ages, crucially addressing the fact that up to 40% of rabies exposures involve children under 15. The label update stems from a successful post-marketing pediatric trial, demonstrating both safety and effectiveness. Kamada anticipates this approval could increase its market share in the estimated $150 million annual U.S. HRIG market.
Kamada Ltd. (NASDAQ: KMDA) reported Q1 2021 revenues of $24.9 million, reflecting a 25% decline from Q1 2020. The net income was $2.7 million or $0.06 per share, down from $5.2 million or $0.12 per share last year. Adjusted EBITDA was $3.7 million, compared to $6.3 million in Q1 2020. Kamada plans to transfer the GLASSIA manufacturing license to Takeda by year-end, receiving $2 million. The company will also downsizes its workforce to cut costs by 10% annually. The Phase 3 InnovAATe trial for inhaled AAT continues, and Kamada remains focused on expanding plasma collection capabilities.
Kamada Ltd. (NASDAQ: KMDA) will announce its financial results for Q1 2021 on May 12, 2021, before the U.S. markets open. Management will hold a conference call at 8:30 AM ET the same day to discuss the results and address inquiries. Kamada's portfolio includes plasma-derived products such as GLASSIA and KEDRAB, with continued production agreements in place with Takeda Pharmaceuticals. The company is also advancing clinical trials for treatments related to COVID-19 and AAT deficiency. Kamada is focused on leveraging its manufacturing capabilities for profitable growth.